SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX) announced its treatment approach for solid tumors in pancreatic cancer, designed by Nuvilex’s acquired company SG Austria, has been endorsed in recent scientific reviews published in the medical literature. These review articles focused on suicide genes and corresponding prodrug conversions for the treatment of various forms of cancer, and featured the value of the Company’s approach to treat pancreatic cancer.
